Stocks

JPMorgan Chase Weighs In on Emergent Biosolutions

Guavy AI Editorial Team Published August 22, 2026

Instruments

JPM

Research analysts at JPMorgan Chase & Co. began coverage of shares of Emergent Biosolutions (NYSE:EBS) in a report issued on Friday, setting an 'underweight' rating for the biopharmaceutical company's stock.

This is not the first time EBS has received a rating from analysts: HC Wainwright dropped their price target to $10.00 and set a 'buy' rating in a research report on Monday, August 10th; Zacks Research upgraded EBS to a 'hold' rating in a report on Tuesday, August 11th.

According to MarketBeat, three equities research analysts have assigned a 'Buy' rating to the company's stock, one has given it a 'Hold', and two have issued a 'Sell' rating. The average rating is currently 'Hold' with a consensus target price of $10.00.

JPMorgan Chase Weighs In on Emergent Biosolutions

Honeywell Workers on Teesside Vote on Strike Action Over Pension Cuts

Honeywell Aerospace Listing Draws Attention, Analysts Predict 35 Percent Increase

Honeywell Rated Buy on Strong Order Growth, Margin Expansion